Search details
1.
ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models.
Blood
; 137(24): 3365-3377, 2021 06 17.
Article
in English
| MEDLINE | ID: mdl-33512452
2.
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
N Engl J Med
; 370(11): 1008-18, 2014 Mar 13.
Article
in English
| MEDLINE | ID: mdl-24450858
3.
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
N Engl J Med
; 370(11): 997-1007, 2014 Mar 13.
Article
in English
| MEDLINE | ID: mdl-24450857
4.
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.
Blood
; 126(25): 2686-94, 2015 Dec 17.
Article
in English
| MEDLINE | ID: mdl-26472751
5.
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.
Blood
; 123(22): 3406-13, 2014 May 29.
Article
in English
| MEDLINE | ID: mdl-24615776
6.
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
Blood
; 123(22): 3390-7, 2014 May 29.
Article
in English
| MEDLINE | ID: mdl-24615777
7.
PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.
Blood
; 119(8): 1897-900, 2012 Feb 23.
Article
in English
| MEDLINE | ID: mdl-22210877
8.
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
Blood
; 118(13): 3603-12, 2011 Sep 29.
Article
in English
| MEDLINE | ID: mdl-21803855
9.
PTC124 targets genetic disorders caused by nonsense mutations.
Nature
; 447(7140): 87-91, 2007 May 03.
Article
in English
| MEDLINE | ID: mdl-17450125
10.
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers.
NEJM Evid
; 1(1): EVIDoa2100001, 2022 01.
Article
in English
| MEDLINE | ID: mdl-38319241
11.
Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.
Am J Respir Crit Care Med
; 182(10): 1262-72, 2010 Nov 15.
Article
in English
| MEDLINE | ID: mdl-20622033
12.
The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy.
Muscle Nerve
; 41(4): 500-10, 2010 Apr.
Article
in English
| MEDLINE | ID: mdl-19941337
13.
The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations.
Muscle Nerve
; 42(6): 966-74, 2010 Dec.
Article
in English
| MEDLINE | ID: mdl-21038378
14.
Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.
Lancet
; 372(9640): 719-27, 2008 Aug 30.
Article
in English
| MEDLINE | ID: mdl-18722008
15.
Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers.
J Clin Pharmacol
; 47(4): 430-44, 2007 Apr.
Article
in English
| MEDLINE | ID: mdl-17389552
16.
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
Clin Cancer Res
; 12(12): 3782-91, 2006 Jun 15.
Article
in English
| MEDLINE | ID: mdl-16778106
17.
A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 58(2): 165-72, 2006 Aug.
Article
in English
| MEDLINE | ID: mdl-16328416
18.
A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience.
Clin Cancer Res
; 11(7): 2644-50, 2005 Apr 01.
Article
in English
| MEDLINE | ID: mdl-15814645
19.
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
J Clin Oncol
; 22(18): 3776-83, 2004 Sep 15.
Article
in English
| MEDLINE | ID: mdl-15365074
20.
Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.
J Clin Oncol
; 20(5): 1182-91, 2002 Mar 01.
Article
in English
| MEDLINE | ID: mdl-11870159